Biomea Fusion Inc. (BMEA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
Biomea Fusion, Inc. (BMEA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BMEA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying about 410% upside from the price used in Citi's call, while his $57 Syndax Pharmaceuticals target points to roughly 190%.
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile.
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Biomea Fusion, Inc. (BMEA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript
Biomea Fusion, Inc. (NASDAQ:BMEA ) Citi's 2025 SMID Cap Biopharma Call Series October 23, 2025 11:00 AM EDT Company Participants Ramses Erdtmann - Co-Founder, President, COO & Director Thorsten Kirschberg - Executive Vice President of Chemistry Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Citigroup Inc., Research Division All right. Hi, everyone.
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know
Biomea Fusion (BMEA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
Biomea Fusion (BMEA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
